Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSTG Biostage	$4.45	$4.45	$4.45 ▼ $4.45	$61.78M	-1.02	1,847 shs	N/A
PLSE Pulse Biosciences	$7.19 -2.3%	$8.87	$3.78 ▼ $13.62	$397.03M	1.67	184,443 shs	180,937 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSTG Biostage	0.00%	0.00%	0.00%	0.00%	-27.64%
PLSE Pulse Biosciences	-1.47%	+1.38%	-21.03%	-11.11%	+27.56%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BSTG Biostage	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSTG Biostage	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSTG Biostage	N/A	N/A	N/A	N/A	($0.26) per share	N/A
PLSE Pulse Biosciences	$700K	567.19	N/A	N/A	$0.81 per share	8.88

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSTG Biostage	-$6.07M	-$0.58	N/A	∞	N/A	N/A	N/A	-174.43%	N/A
PLSE Pulse Biosciences	-$42.21M	-$0.89	N/A	∞	N/A	N/A	-112.74%	-61.09%	5/9/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSTG Biostage	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSTG Biostage	N/A	2.73	2.73
PLSE Pulse Biosciences	N/A	6.76	6.76

Ownership

Institutional Ownership

Company	Institutional Ownership
BSTG Biostage	N/A
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
BSTG Biostage	15.30%
PLSE Pulse Biosciences	69.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BSTG Biostage	7	13.88 million	11.76 million	Not Optionable
PLSE Pulse Biosciences	61	55.22 million	16.73 million	Optionable

PLSE and BSTG Headlines

Source	Headline
	Pulse Biosciences (NASDAQ:PLSE) Stock Crosses Below 50 Day Moving Average of $8.98 americanbankingnews.com - April 13 at 5:00 AM
	Pulse Biosciences to raise $60M massdevice.com - March 29 at 10:48 AM
	Q4 2023 Pulse Biosciences Inc Earnings Call finance.yahoo.com - March 29 at 10:48 AM
	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023 investorplace.com - March 28 at 11:31 PM
	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 finance.yahoo.com - March 28 at 7:45 PM
	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results businesswire.com - March 28 at 4:12 PM
	Pulse Biosciences Announces Plans to Initiate a Rights Offering businesswire.com - March 28 at 4:10 PM
	Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 4.7% marketbeat.com - March 19 at 12:47 PM
	PLSE Apr 2024 25.000 call finance.yahoo.com - March 17 at 10:01 AM
	PLSE Oct 2024 17.500 call finance.yahoo.com - March 17 at 12:13 AM
	PLSE Oct 2024 12.500 call finance.yahoo.com - March 16 at 2:13 PM
	PLSE Jul 2024 2.500 put finance.yahoo.com - March 16 at 2:13 PM
	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 businesswire.com - March 14 at 4:05 PM
	Pulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearance msn.com - March 13 at 7:07 PM
	FDA clears pulsed field ablation electrode tech from Pulse Biosciences massdevice.com - March 11 at 1:28 PM
	What to know about low blood pressure with a high pulse medicalnewstoday.com - March 10 at 2:46 PM
	FDA clears Pulse Biosciences' soft tissue ablation system investing.com - March 10 at 2:46 PM
	Pulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode System markets.businessinsider.com - March 9 at 1:21 AM
	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode System stockhouse.com - March 8 at 3:19 PM
	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System businesswire.com - March 8 at 1:17 PM
	Pulse Biosciences reports positive 60-day evaluations for AFib-treating pulsed field ablation massdevice.com - February 14 at 12:51 PM
	Pulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Up markets.businessinsider.com - February 14 at 12:51 PM
	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study finance.yahoo.com - February 14 at 12:51 PM
	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study businesswire.com - February 14 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Biostage

OTCMKTS:BSTG

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

Pulse Biosciences

NASDAQ:PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial